CTOs on the Move

DiagnosisONE Inc.

www.diagnosisone.com

 
DiagnosisONE Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mash Medical Aid Supply House

Mash Medical Aid Supply House is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lasering USA

Lasering USA is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimensions Healthcare System

Dimensions Healthcare System is an integrated not-for-profit, community-owned organization comprised of two hospitals and several other healthcare facilities providing comprehensive, quality healthcare services to the residents of Prince George`s County, Maryland and surrounding areas. Both hospitals within Dimensions Healthcare System have been recognized by U.S. News & World Report. Dimensions Healthcare System is the largest healthcare system headquartered in Prince George`s County.

I Am Boundless

I Am Boundless provides community based supports and services for individuals with intellectual and behavioral developmental disabilities.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.